NCM · Financial Statements
MoonLake Immunotherapeutics (MLTX) Financial Statements
$10.82
NCM: MLTX
Market Cap $910.13M
Overview Financials Dividend MoonLake Immunotherapeutics most recently reported annual revenue of $0, net profit of $-227.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-54.0M $-65.0M $-54.0M $-143.0M $-245.0M Net Profit $-54.0M $-50.0M $-36.0M $-119.0M $-227.0M EPS $-1.45 $-1.70 $-0.73 $-1.89 $-3.53 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $10.0M $77.0M $527.0M $478.0M $424.0M Total Liabilities $21.0M $8.0M $13.0M $25.0M $120.0M Cash $8.0M $40.0M $451.0M $180.0M $335.0M Borrowings $15.0M $0 $4.0M $3.0M $76.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-35.0M $-56.0M $-43.0M $-117.0M $-196.0M Investing Cash Flow $0 $-32.0M $-25.0M $-206.0M $203.0M Financing Cash Flow $0 $135.0M $-3.0M $-1.0M $0 Net Cash Flow $7.0M $31.0M $412.0M $-271.0M $154.0M Free Cash Flow $-35.0M $-56.0M $-43.0M $-117.0M $-196.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.09 EV / EBITDA -2.33 FCF Yield -23.46% Quick Ratio 12.56 Interest Coverage -26.58 Return 1Y -65.27% Return 3Y -64.13% Return 5Y 93.60%
Screens featuring this stock